Generated by AI
China Pharma Holdings, Inc. is a specialty pharmaceutical company focused on the development, manufacture, and marketing of human-use medicines in China. Its current portfolio covers products for central nervous system and cerebral-cardiovascular disorders, anti-infection and respiratory conditions, digestive diseases, comprehensive healthcare, and protective products. The company offers pharmaceuticals in multiple dosage forms, including injectables, tablets, capsules, and oral solutions, serving hospitals and private retailers across its domestic market. China Pharma Holdings, Inc. operates as a vertically integrated drug manufacturer, combining research, production, and commercialization within its business model. Based in Haikou, China, the company plays a role in supplying medicines for widely prevalent medical conditions in the Chinese healthcare market.
WebsiteNo. 17, Jinpan Road
Haikou, 570216
China
The latest articles about CPHI.
The nation’s innovative drug out-licensing deals reached US$130 billion by the end of September, almost matching 2025’s full-year level.
Summary of Oct 14's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Summary of Oct 13's posts. Generated by AI.
Investors talking about CPHI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.